Stay updated on Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a minor page update or bug fix. It does not appear to modify the study details, eligibility criteria, or results on the page.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedPage revision updated from v3.5.3 to v3.5.4. This update is a metadata/version bump and does not change the study content or user-facing information.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page’s footer revision/version has been updated from v3.5.2 to v3.5.3, reflecting a site interface update rather than a change to the clinical trial record.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Revision: v3.5.2; Removed Revision: v3.5.0.SummaryDifference0.1%

- Check83 days agoChange DetectedVersion bump from v3.4.3 to v3.5.0; no visible changes to study details or page content are indicated.SummaryDifference0.1%

- Check90 days agoChange DetectedUpdated from revision v3.4.2 to v3.4.3. This appears to be a minor internal version update with no visible changes to study details or user-facing features.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.